Clinical Trial

HS-IT101 Injection in the Treatment of Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 2, 2024 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced solid tumor.
Trial Details
NCT Number NCT06342336
Lead Sponsor Qingdao Sino-Cell Biomedicine Co., Ltd.
Collaborators: Cancer Institute and Hospital, Chinese Academy of Medical Sciences, The First Hospital of Jilin University, West China Hospital
Conditions Solid Tumor
Enrollment 44 participants
Start Date 2024-01-18
Primary Completion 2026-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-02